LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of CorMedix Inc. (“CorMedix”) (NYSE AMEX: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease. “CorMedix is expected to advance two important products into Phase III clinical trials next year,” commented Andrew I. McDonald, Ph.D., Managing Director at LifeSci Advisors. “Neutrolin, in particular, for catheter-related bloodstream infections, has already demonstrated an excellent safety and efficacy profile in initial studies for this life-threatening indication. Should these results be replicated in Phase III, CorMedix will be poised to capture a significant portion of this ~$800MM market opportunity upon regulatory approval and commercialization.” LifeSci Advisors’ 47-page Initiation Report contains a detailed discussion of CorMedix’s lead pipeline candidates, Neutrolin (CRMD003), a catheter lock solution preventing infection and clotting in hemodialysis catheters, and Deferiprone (CRMD001), an oral iron chelator that has well-documented efficacy and safety in iron-overload disorders. The report discusses the current clinical advancements of both products. Neutrolin achieved proof of concept demonstrating a significantly higher CRBI-free survival relative to a heparin control (94% vs. 47%, P<0.001) and the Company plans to initiate a Pivotal trial in 1H2011 with approximately 400 ESRD patients. It is estimated that an antimicrobial lock solution will reduce CRBIs by 50% substantially reducing costs associated for treating infected patients. Alternatively, Deferiprone’s Phase II trial for patients with CIN is expected to read out in 2H2011 before the initiation of an 800-patient Phase III trial. Deferiprone is currently approved for sale in 50 countries worldwide (ex-U.S.) for the treatment of iron overload in patients with Thalassemia Major. The report further highlights both compounds’ history and background, competitive landscape, upcoming expected milestones, relevant market dynamics, and risks.
Dr. McDonald’s full Initiation Report is available to download at no cost at the LifeSci Advisors website, www.lifesciadvisors.com. In addition to this Initiation Report, LifeSci Advisors will also provide ongoing coverage and event-based research updates on CorMedix as developments occur.The LifeSci Advisors research team is led by Dr. Andrew I. McDonald, an industry veteran with more than 15 years of healthcare industry experience. Prior to co-founding LSA, Dr. McDonald was the Senior Biotechnology Analyst at Great Point Partners, a leading health care investment firm with over $500 million under management. Before Great Point, he was Co-head of Healthcare Research and Lead Biotechnology Analyst at ThinkEquity Partners, a boutique investment banking firm focused on growth companies. Dr. McDonald holds a Ph.D. in organic chemistry from the University of California, Irvine, and, earlier in his career, worked as a medicinal chemist at both Pfizer and Cytokinetics. About CorMedix: CorMedix Inc. is a pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac and renal dysfunction, also known as cardiorenal disease. CorMedix’s goal is to treat kidney disease by reducing the commonly associated cardiovascular and metabolic complications, in effect, treating the kidney to treat the heart. CorMedix currently has several product candidates in development, including its two most advanced product candidates: CRMD-003 (Neutrolin®) for the prevention of central venous catheter infection and clotting in hemodialysis; and CRMD-001 (a proprietary formulation of deferiprone) for the prevention of contrast-induced nephropathy in high-risk patients with chronic kidney disease. Please see www.cormedix.com for additional information. About LifeSci Advisors: LifeSci Advisors (LSA) is a leading research firm and communications consultancy dedicated to the life sciences industry. The firm provides strategic counsel, customized marketing communications, comprehensive research reports and investor relations services to companies that specialize in the discovery, development and commercialization of drugs, drug delivery systems, medical devices and diagnostics. To learn more about LSA, visit the company’s website, www.lifesciadvisors.com. Important Disclosures: The research report described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in LSA research reports may be unsuitable for some investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider LSA reports as only a single factor in making their investment decisions and should not rely solely on these reports in evaluating whether or not to buy or sell the securities of the subject company. LifeSci Advisors has been compensated by the company that is the subject of the report described and future research reports, investor relations services, and general consulting services. Please read each report's full disclosures and analyst background on the LSA website, www.lifesciadvisors.com, before investing. LifeSci Advisors is not a registered investment adviser or broker-dealer. Forward-looking statements: This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent LSA's judgment as of the date of this release. LifeSci Advisors disclaims, however, any intent or obligation to update these forward-looking statements.